Insiders · ONCT

ONCT insider transactions

Oncternal Therapeutics Inc. (ONCT) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

ONCT insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Oncternal Therapeutics Inc., latest first. Follow anyone to get their next filing.

• Daniel L KisnerDirector
• Michael G CarterDirector
• William R LarueDirector
• David F HaleDirector+$8,859-$17.4K
• Charles TheuerDirector
• Jill DeSimoneDirector, since January 2023
• Rosemary MazanetDirector, since January 2021
• Robert James WillsDirector+$86.3K-$8,859
• James B BreitmeyerChief Executive Officer, Director+$86K
• Chase C. LeavittGeneral Counsel/Secretary+$38.7K
• Salim YazjiChief Medical Officer, since May 2021+$24.1K
• Rajesh KrishnanCTO/cso, since May 2021
• Richard G VincentChief Financial Officer+$37.8K
• Xin NakanishiDirector
• Gunnar F. KaufmannOfficer+$9,824
• Jinzhu PhD ChenDirector
• Igor BilinskyOfficer

Recent Form 3, 4, and 5 filings for ONCT

• 872d
  SEC Form 4 filed by Director Kisner Daniel L

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 872d
  SEC Form 4 filed by Director Carter Michael G

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 872d
  SEC Form 4 filed by Director Larue William R

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 872d
  SEC Form 4 filed by Director Desimone Jill

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 872d
  SEC Form 4 filed by Director Theuer Charles

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 872d
  SEC Form 4 filed by Director Hale David F

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 872d
  SEC Form 4 filed by Director Wills Robert James

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 872d
  SEC Form 4 filed by Director Mazanet Rosemary

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 947d
  Wills Robert James bought $27,655 worth of shares (3,086 units at $8.96), increasing direct ownership by 45% to 10,000 units (SEC Form 4)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 956d
  Wills Robert James bought $58,602 worth of shares (6,914 units at $8.48) (SEC Form 4)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 990d
  Wills Robert James sold $8,859 worth of shares (980 units at $9.04), closing all direct ownership in the company (SEC Form 4)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 990d
  Hale David F bought $8,859 worth of shares (980 units at $9.04) (SEC Form 4)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1002d
  SEC Form 4 filed by Breitmeyer James B

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1002d
  SEC Form 4 filed by Leavitt Chase C.

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1002d
  SEC Form 4 filed by Yazji Salim

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1002d
  SEC Form 4 filed by Krishnan Rajesh

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1002d
  SEC Form 4 filed by Vincent Richard G

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1043d
  Krishnan Rajesh covered exercise/tax liability with 11,838 shares, decreasing direct ownership by 21% to 44,019 units (SEC Form 4)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1043d
  Yazji Salim covered exercise/tax liability with 19,742 shares, decreasing direct ownership by 13% to 128,635 units (SEC Form 4)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1043d
  Vincent Richard G covered exercise/tax liability with 8,868 shares, decreasing direct ownership by 6% to 140,922 units (SEC Form 4)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1043d
  Leavitt Chase C. covered exercise/tax liability with 11,838 shares, decreasing direct ownership by 12% to 84,758 units (SEC Form 4)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1043d
  Breitmeyer James B covered exercise/tax liability with 55,440 shares, decreasing direct ownership by 10% to 443,034 units (SEC Form 4)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1136d
  SEC Form 4 filed by Leavitt Chase C.

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1136d
  SEC Form 4 filed by Yazji Salim

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1136d
  SEC Form 4 filed by Breitmeyer James B

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1136d
  SEC Form 4 filed by Vincent Richard G

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1136d
  SEC Form 4 filed by Krishnan Rajesh

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1227d
  SEC Form 4 filed by Breitmeyer James B

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1227d
  SEC Form 4 filed by Leavitt Chase C.

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1227d
  SEC Form 4 filed by Vincent Richard G

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1227d
  SEC Form 4 filed by Yazji Salim

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1227d
  SEC Form 4 filed by Krishnan Rajesh

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1232d
  SEC Form 4 filed by Mazanet Rosemary

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1232d
  SEC Form 4 filed by Larue William R

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1232d
  SEC Form 4 filed by Carter Michael G

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1232d
  SEC Form 4 filed by Theuer Charles

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1232d
  SEC Form 4 filed by Hale David F

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1232d
  SEC Form 4 filed by Kisner Daniel L

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1232d
  SEC Form 4 filed by Desimone Jill

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1232d
  SEC Form 4 filed by Nakanishi Xin

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1232d
  SEC Form 4 filed by Wills Robert James

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1248d
  SEC Form 4 filed by Kaufmann Gunnar F.

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1307d
  SEC Form 4 filed by Breitmeyer James B

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1309d
  SEC Form 4 filed by Yazji Salim

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1310d
  SEC Form 4 filed by Vincent Richard G

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1310d
  SEC Form 4 filed by Leavitt Chase C.

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1358d
  SEC Form 4 filed by Breitmeyer James B

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1359d
  SEC Form 4 filed by Yazji Salim

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1359d
  SEC Form 4 filed by Leavitt Chase C.

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1359d
  SEC Form 4 filed by Vincent Richard G

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1359d
  SEC Form 4 filed by Krishnan Rajesh

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1359d
  SEC Form 4 filed by Kaufmann Gunnar F.

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1408d
  SEC Form 4 filed by Desimone Jill

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1408d
  SEC Form 3 filed by new insider Desimone Jill

  3 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1408d
  SEC Form 4: Breitmeyer James B covered exercise/tax liability with 29,118 shares, decreasing direct ownership by 5% to 541,981 units (tax withholding)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1408d
  SEC Form 4: Krishnan Rajesh covered exercise/tax liability with 6,238 shares, decreasing direct ownership by 9% to 66,754 units to cover withholding tax

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1408d
  SEC Form 4: Leavitt Chase C. covered exercise/tax liability with 6,091 shares, decreasing direct ownership by 7% to 81,901 units to cover withholding tax

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1408d
  SEC Form 4: Yazji Salim covered exercise/tax liability with 9,961 shares, decreasing direct ownership by 7% to 139,676 units (withholding obligation)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1408d
  SEC Form 4: Kaufmann Gunnar F. covered exercise/tax liability with 6,266 shares, decreasing direct ownership by 9% to 66,726 units (withholding obligation)

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
• 1408d
  SEC Form 4: Vincent Richard G covered exercise/tax liability with 4,428 shares, decreasing direct ownership by 3% to 126,859 units to satisfy tax liability

  4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)